Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jared Darveaux

Allergy & Immunology Onalaska, WI Medical Doctor

NPI 1306140439 CMS profile 882968

311 Gundersen Dr, Onalaska, WI 54650

Open in the dashboard

General payments

$286,876

301 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$83,321 paid to institutions, not to them · program years 2019–2025

Through program year 2025, Jared Darveaux of Onalaska, WI is reported in the CMS Open Payments database as having received $286,876 across 301 general payments and $0 in research payments paid to them. Separately, studies naming them as principal investigator received $83,321 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 97th percentile of Allergy & Immunology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $45,115 35
2024 General $48,980 46
2023 General $41,824 56
2022 General $27,430 30
2021 General $41,852 40
2020 General $22,865 34
2019 General $58,811 60

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jared Darveaux
  • Allergy & Immunology median
  • Middle half of Allergy & Immunology
  • National median

In program year 2025, general payments to Jared Darveaux were reported at $45,115. Among 336 Allergy & Immunology profiles paid that year, the median was $682 and the middle half received between $143 and $2,317.

Show as a table
Year Jared Darveaux Allergy & Immunology median Middle half National median
2019 $58,811 $378 $115–$1,178 $163
2020 $22,865 $303 $75–$1,581 $114
2021 $41,852 $407 $122–$1,475 $132
2022 $27,430 $357 $120–$1,340 $149
2023 $41,824 $445 $124–$1,536 $160
2024 $48,980 $541 $129–$1,763 $164
2025 $45,115 $682 $143–$2,317 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Genzyme Corporation $91,165 60 payments
  2. GlaxoSmithKline, LLC. $66,328 53 payments
  3. Regeneron Healthcare Solutions, Inc. $65,382 98 payments
  4. AstraZeneca Pharmaceuticals LP $59,364 81 payments
  5. Amgen Inc. $3,860 4 payments
  6. Sanofi Pasteur Inc. $495 1 payment
  7. Novartis Pharmaceuticals Corporation $176 2 payments
  8. Incyte Corporation $55 1 payment
  9. Ionis Pharmaceuticals, Inc. $50 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $261,355 126 payments
  2. Travel and Lodging $17,122 68 payments
  3. Food and Beverage $7,904 106 payments
  4. Grant $495 1 payment
Products named General payments · program years 2019–2025
  1. DUPIXENT Immunology $85,369 54 payments
  2. DUPIXENT Inflammation And Immunology $60,466 95 payments
  3. NUCALA Immunology $39,899 32 payments
  4. NUCALA Respiratory $26,384 20 payments
  5. FASENRA Respiratory $23,574 40 payments
  6. FASENRA Respiratory $18,779 18 payments
  7. TEZSPIRE Respiratory $11,044 14 payments
  8. DUPIXENT Immunology $9,306 8 payments
  9. TEZSPIRE Inflammation $2,910 3 payments
  10. DUPIXENT Immunology And Inflammation $2,543 2 payments
  11. Other $213 5 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 36 drugs

Part D claims

3,005

Median for Allergy/ Immunology: 449

Drug cost

$1,566,079

Median for Allergy/ Immunology: $169,700

Branded share of claims

60.1%

Median for Allergy/ Immunology: 37.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Dupixent Pen Dupilumab Brand 105 $405,098
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 430 $317,637
Dupixent Syringe Dupilumab Brand 50 $251,452
Fasenra Pen Benralizumab Brand 26 $147,324
Breo Ellipta Fluticasone/Vilanterol Brand 138 $71,912
Xolair Omalizumab Brand 24 $63,537
Spiriva Respimat Tiotropium Bromide Brand 77 $45,434
Dulera Mometasone/Formoterol Brand 94 $34,105
Fluticasone-Salmeterol Fluticasone Propion/Salmeterol Brand 195 $31,776
Budesonide-Formoterol Fumarate Budesonide/Formoterol Fumarate Brand 124 $31,426

The 10 drugs with the highest cost, of 36 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 3,579 Part D prescribers listed as Allergy/ Immunology; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 28 billing codes

Paid by Medicare

$37,454

Medicare's payments for the services billed

Medicare patients

274

Average age 70

Services billed

1,615

169 women, 105 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 60%
Arthritis 45%
Depression 26%
Chronic kidney disease 24%
Diabetes 21%
Osteoporosis 20%
COPD 18%
Ischemic heart disease 16%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

5 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
DUPIXENT
  • GENZYME CORPORATION $27,873
  • Regeneron Healthcare Solutions, Inc. $4,866
$32,738 155 —
NUCALA
  • GlaxoSmithKline, LLC. $9,981
$9,981 — —
FASENRA
  • AstraZeneca Pharmaceuticals LP $5,340
$5,340 26 —
TEZSPIRE
  • AstraZeneca Pharmaceuticals LP $250
$250 — —
XOLAIR
  • Novartis Pharmaceuticals Corporation $84
$84 24 —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

Records

301 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Allergy & Immunology in Wisconsin

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record